Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.57 |
| ▸ | MAOB | P27338 | 9/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14218805 | 0.91 | HRH3 (0.59) | HRH3MAOB | |
| SCHEMBL19509695 | 0.87 | HRH3 (0.58) | HRH3MAOBNPC1MAPTRAB9A | |
| SCHEMBL12264003 | 0.85 | SMN1; SMN2 (0.49) | HRH3MAOB | |
| SCHEMBL13930848 | 0.85 | HRH3 (0.43) | HRH3MAOB | |
| SCHEMBL10084514 | 0.85 | HRH3 (0.64) | HRH3MAOB | |
| SCHEMBL11125566 | 0.84 | CYP3A4 (0.70) | HRH3MAOBMAPT | |
| SCHEMBL15723550 | 0.82 | SMN1; SMN2 (0.56) | MAPT | |
| SCHEMBL1535647 | 0.82 | KDM4E (0.54) | HRH3NPC1MAPTRAB9A | |
| SCHEMBL20349668 | 0.82 | SMN1; SMN2 (0.42) | HRH3MAOB | |
| SCHEMBL18737502 | 0.81 | SMN1; SMN2 (0.60) | HRH3MAOBNPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174019-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-13 | — | — | US | disclosed |
| US-8436103-B2 | Star polymer and method of producing the same | NIPPON SODA CO., LTD. (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20090118436-A1 | Star Polymer and Method of Producing the Same | NIPPON SODA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090054472-A1 | Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof | TEIJIN PHARMA LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1824837-B1 | SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054472-A1 | Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | HRH3 2746/4885MAOB 4400/4885NPC1 3958/4885 |
| US-10174019-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | CYP3A5, PAICS, CYP4B1 | HRH3 1577/4885MAOB 1218/4885NPC1 197/4885 |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | HRH3 2521/4885MAOB 2519/4885NPC1 3346/4885 |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | HRH3 539/4885MAOB 230/4885NPC1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.